FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents a thermally-sensitive liposome for treating cancer in a subject, containing at least one phosphatidylcholine, at least one phosphatidylglycerol, monostearoyl phosphatidylcholine, pegylated phospholipid and an active substance specified in a group consisting of taxotere, docetaxel and carboplatin wherein the liposome has a gel to liquid transition point from approximately 39°C to approximately 45°C.
EFFECT: invention provides storage-stability for a long period of time of one month or more at low temperatures.
9 cl, 8 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL COMPOSITION FOR APPLICATION IN PERITONEAL DIALYSIS | 2013 |
|
RU2609860C2 |
| HYPER-STABILIZED LIPOSOMES INCREASING DIRECTED TARGETING OF MITOTIC CELLS | 2018 |
|
RU2765736C2 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
| COMBINATION LIPOSOMAL COMPOSITIONS FOR CANCER TREATMENT | 2012 |
|
RU2640934C2 |
| CREATING CONTROLLED RELEASE PROFILE OF DRUG SUBSTANCE USING LIPOSOMAL COMPOSITION IN AQUEOUS AND ANHYDROUS SOLUTIONS | 2014 |
|
RU2712157C2 |
| PREORAL DELIVERY SYSTEM FOR PROTEIN SUBSTANCE (OPTIONS), PROTECTIVE COATING FOR DELIVERY SYSTEM (OPTIONS) | 2014 |
|
RU2665367C2 |
| TREATMENT OF PANCREATIC CANCER | 2018 |
|
RU2792690C2 |
| USE OF MITOXANTHRON LIPOSOME FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA | 2019 |
|
RU2804477C2 |
| LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
| LIPOSOMAL COMPOSITION, NEUTRAL LIPOPOLYMER AND METHOD FOR ELONGATION OF LIPOSOME CIRCULATING TIME | 2000 |
|
RU2250911C2 |
